Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

February 05, 2024

JPMorgan Chase becomes the latest institution in the company's bull pen.

Why Beam Therapeutics Stock Zoomed 17% Higher Today ↗

January 29, 2024

Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)

2 gene editing stocks to keep on your 2024 watchlist

January 23, 2024

Via MarketBeat

Is Beam Therapeutics Stock a Buy Now? ↗

November 18, 2023

It has plenty of money, but it'll be facing plenty of competition, too.

Bitcoin, Ethereum, Dogecoin Rise As Investors Weigh Spot ETF Impact: Analyst Says Scenario For King Crypto Is 'Rejection' At $46K And Then Correction To Below $40K ↗

Beam Therapeutics: Q3 Earnings Insights ↗

November 08, 2023

Via Benzinga

January 16, 2024

Major cryptocurrencies on Tuesday evening posted some gains following a weekend characterized by

Via Benzinga

Topics ETFs

Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market ↗

January 16, 2024

Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry.

Analysts have high hopes for these three innovation companies in 2024.

3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street ↗

January 16, 2024

As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.

3 Stocks to Buy in the Booming Field of Gene Editing ↗

January 11, 2024

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

January 08, 2024

Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run.

4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 ↗

January 08, 2024

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

Wall Street is uber-bullish on these two Ark Invest holdings.

2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street ↗

December 27, 2023

On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for

CRISPR Therapeutics sets sights on gene-editing cures for disease

December 27, 2023

Via MarketBeat

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

December 14, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Lululemon To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday ↗

December 08, 2023

Via Benzinga

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception ↗

November 29, 2023

The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014.

Via Benzinga

Topics ETFs

The 3 Best Gene Editing Stocks on the Frontier of Medicine ↗

November 20, 2023

Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December.

These stocks could grow much larger over the next few years.

3 Monster Stocks in the Making ↗

November 18, 2023

Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks ↗

November 14, 2023

You might not get a better chance to invest in these disruptive companies.

Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

November 13, 2023

Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results.

Via Benzinga

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

November 08, 2023

Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

November 08, 2023

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners ↗

November 06, 2023

Roku vaulted 50% to become Ark Innovation's top holding.

Via Investor's Business Daily

2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now ↗

November 05, 2023

These two beaten-down growth stocks could be brilliant buys for risk-tolerant investors.

Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on.

Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On ↗

November 01, 2023

Lilly is putting its money where its mouth is with its purchase of cutting-edge medical technology.

Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today ↗

October 31, 2023